Epidemiology, virulence factors and management of the pneumococcus
- PMID: 27703671
- PMCID: PMC5031122
- DOI: 10.12688/f1000research.9283.1
Epidemiology, virulence factors and management of the pneumococcus
Abstract
Pneumococcal infections continue to cause significant morbidity and mortality in patients throughout the world. This microorganism remains the most common bacterial cause of community-acquired pneumonia and is associated with a considerable burden of disease and health-care costs in both developed and developing countries. Emerging antibiotic resistance has been a concern because of its potential negative impact on the outcome of patients who receive standard antibiotic therapy. However, there have been substantial changes in the epidemiology of this pathogen in recent years, not least of which has been due to the use of pneumococcal conjugate vaccines in children, with subsequent herd protection in unvaccinated adults and children. Furthermore, much recent research has led to a better understanding of the virulence factors of this pathogen and their role in the pathogenesis of severe pneumococcal disease, including the cardiac complications, as well as the potential role of adjunctive therapy in the management of severely ill cases. This review will describe recent advances in our understanding of the epidemiology, virulence factors, and management of pneumococcal community-acquired pneumonia.
Keywords: Antibiotic resistance; Streptococcus pneumoniae; adjunctive therapy; community-acquired pneumonia.
Conflict of interest statement
Charles Feldman has acted on the advisory board or speakers’ bureau (or both) of pharmaceutical companies manufacturing or marketing macrolide antibiotics and pneumococcal conjugate vaccines (Abbott, Aspen, Pfizer, and Sandoz). Ronald Anderson declares that he has no competing interests. Competing interests: Mathias Pletz has acted on the advisory board and/or speaker’s bureau of pharmaceutical companies manufacturing or marketing antibiotics and pneumococcal conjugate vaccines (Astrazeneca, Pfizer, Novartis, MSD, Basilea). No competing interests were disclosed.
References
-
- Shibl AM, Memish ZA, Ibrahim E, et al. : Burden of adult community-acquired pneumonia in the Middle East/North Africa region. Rev Med Microbiol. 2010;21(1):11–20. 10.1097/MRM.0b013e3283377af7 - DOI
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
